•  
  •  
image-625819-Biogen_logo.png
image-723912-Tango_Logo.jpg
              
                   251AD201 

 
Below, please find a brief summary of the Biogen 251AD201 (TANGO) trial, an anti-tau vaccine (BIIB092) Phase 2 trial designed to slow down the progression of disease for individuals with mild dementia and MCI, due to Alzheimer's


  • Drug administration -- monthly IV infusion   

  • Age range -- 50-80

  • MMSE range -- 22-30

  • Study Duration -- 18 mos. + safety followup

  • Target population -- MCI or Mild Dementia  due to Alzheimer's                                                                          

  • Mechanism of action -- passive antibody to tau protein

  • Randomization split -- 2:1,  active:placebo

  • Type(s) of imaging -- brain MRI, amyloid PET, tau PET


For more details on this specific trial, visit:

    
                                                                        ClinicalTrials.gov
       
                                                               A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060